HUTCHMED (China) Limited (HCM)
HCM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$13.50
-1.32% on the day
Market cap
$2.4B
Mid cap
Revenue · 2025
$548.5M
-13.0% on 2024
Net income · 2025
$456.9M
83.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | HCM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Hong Kong |
| IPO year | 2016 |
| SEC CIK | 0001648257 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | E9 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $548.5M |
| Net income | $456.9M |
| Operating income | -$39.2M |
| Net margin | 83.3% |
| Operating margin | -7.1% |
| Revenue growth | -13.0% |
| Cash | $71.3M |
| Total assets | $1.8B |
| P/E (computed) | 5.2× |
| P/S (computed) | 4.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2021-06-24 |
| Latest annual report | 20-F | 2026-03-05 |
| Latest quarterly / interim | 6-K | 2026-09-29 |
Source: SEC EDGAR submissions feed, 605 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.8% |
| 1 month | -1.4% |
| 3 months | +17.1% |
| Year to date | +2.0% |
| 1 year | -11.6% |
| From 52-week high | -15.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MBX | MBX Biosciences Inc. | $49.00 | -5.80% | $2.4B |
| LQDA | Liquidia Corporation | $26.81 | -3.11% | $2.4B |
| NAMS | NewAmsterdam Pharma Company N.V. | $20.19 | -4.99% | $2.4B |
| PBH | Prestige Consumer Healthcare Inc. | $48.50 | -1.02% | $2.3B |
| NRIX | Nurix Therapeutics Inc. | $22.13 | -0.14% | $2.3B |
| SUPN | Supernus Pharmaceuticals Inc. | $42.01 | -1.87% | $2.4B |
| SLS | SELLAS Life Sciences Group Inc. | $12.41 | +4.02% | $2.5B |
| BHC | Bausch Health Companies Inc. | $5.89 | -0.68% | $2.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier